MOTS-c Questions — Answered from the Published Record

MOTS-c activates AMPK via the folate-purine-AICAR axis, enhancing glucose uptake in skeletal muscle via GLUT4 translocation and promoting fatty acid beta-oxidation. Under metabolic stress it translocates to the nucleus, binding NRF2 to upregulate antioxidant genes. A 2024 study identified CK2alpha as a direct binding partner.^[12] Primary tissue targets are skeletal muscle, liver, and adipose.^[1][4][17]

A 16-amino-acid peptide (sequence: MRWQEMGYIFYPRKLR) encoded by a short open reading frame within the mitochondrial 12S rRNA gene (MT-RNR1). Molecular weight 2174.6 Da, highly conserved across 14 species. One of the first peptide hormones known to be encoded by the mitochondrial genome rather than the nuclear genome.^[1] Endogenous — produced naturally by human cells — but prohibited in sport when administered exogenously.

Mouse studies show exogenous MOTS-c increases treadmill running capacity and recapitulates AMPK-driven metabolic reprogramming similar to exercise.^[2] Human exercise induces an 11.9-fold increase in skeletal muscle MOTS-c expression and a 1.5-fold rise in circulating MOTS-c.^[3] Whether exogenous administration fully replicates exercise-training adaptations in humans is not established — no controlled human exercise trial has been published.

Yes — MOTS-c is an endogenous peptide produced by human mitochondria and circulates in plasma. Exercise elevates circulating and intramuscular MOTS-c in healthy adults.^[3] The WADA prohibition applies to the exogenously administered synthetic analog, not to the naturally circulating peptide the body produces on its own.

Yes, substantially. MOTS-c is 16 amino acids, encoded by MT-RNR1 (12S rRNA); humanin is 21 amino acids, encoded by MT-RNR2 (16S rRNA). MOTS-c primarily targets skeletal muscle metabolic regulation via intracellular AMPK/AICAR; humanin targets neuroprotection and anti-apoptosis via cell-surface receptors FPRL-1/2 and CNTFR alpha. Primary tissues: MOTS-c (muscle, liver, adipose) vs humanin (brain, retina, gonads).^[18]

Yes. MOTS-c is prohibited at all times under WADA S4.4.1 (Activators of AMP-activated protein kinase / Metabolic Modulators). This covers both in-competition and out-of-competition use. USADA confirms MOTS-c has no approved medical use and no TUE pathway. Note: the correct category is S4.4.1, not S2 — some sources misreport the classification.

No. USADA states MOTS-c has no approved medical use and therefore no TUE would be granted. MOTS-c is not an approved drug in any jurisdiction. Athletes subject to anti-doping testing must treat it as prohibited under all circumstances with no exemption pathway.

MOTS-c has no FDA-approved indication and is not an approved drug in any jurisdiction as of 2025. No timeline for approval exists. Compounding pharmacies are prohibited from manufacturing MOTS-c products under FDA guidelines. The native sequence has not entered late-phase clinical trials.

USADA warns that MOTS-c may appear in dietary supplements without clear labeling. Given its WADA S4.4.1 prohibited status, athletes should treat any supplement carrying mitochondria-support or AMPK-activator language with caution. There is a documented contamination risk in the unregulated supplement market.

No standard or therapeutic dose exists — none has been established in a controlled clinical trial. Preclinical studies used 0.5–15 mg/kg/day in mice via intraperitoneal or subcutaneous injection.^{[1][2][5][10][11]} Human self-experiment protocols typically report 5–10 mg/week subcutaneous, but this is not from peer-reviewed trials.

Mouse studies in the Reynolds 2021 endurance arm administered MOTS-c before treadmill exercise sessions.^[2] No circadian or meal-timing optimization data from human trials exist. No published study has characterized pre-workout versus fasted versus post-meal administration in humans.

Lyophilized MOTS-c is typically reconstituted with bacteriostatic water (1–2 mL per 10 mg vial in research protocols), stored at 4°C for short-term use or at -20°C for longer periods. Repeated freeze-thaw cycles should be avoided as they reduce peptide integrity. This describes research-context handling of a chemical reagent.

Rodent studies show measurable metabolic improvements after two to four weeks of daily administration.^[1] The 2019 metabolomics study showed measurable plasma metabolite changes after three days at 2.5 mg/kg BID.^[5] No controlled human trial has characterized time-to-effect for exogenous MOTS-c.

Oral administration faces rapid proteolytic degradation in the gastrointestinal tract. Some animal studies used oral delivery at higher doses, but oral bioavailability has not been validated in comparative PK studies. Subcutaneous injection is the route used in virtually all published efficacy studies.^[2][10]

USADA-documented self-experiment reports include palpitations, injection-site reactions, insomnia, fatigue, and fever. The key mechanistic concern is folate-pathway disruption: MOTS-c inhibits the folate cycle, which could theoretically impair one-carbon methylation reactions with extended use.^[17] Long-term safety in humans has not been characterized in any controlled study. No Phase 2/3 safety trial data exist.

Published interventional literature (rodent models) reports: improved insulin sensitivity and reduced adiposity^[1]; twofold increase in treadmill running distance in middle-aged and old mice^[2]; prevention of glucocorticoid-induced atrophy in human myotubes in vitro^[13]; improved cardiac function in pressure-overload mouse model^[10]; and restored mitochondrial respiration in diabetic rat heart.^[11] Human interventional data are absent.

Rodent data show MOTS-c improves hepatic insulin sensitivity and reduces liver fat in obese models.^[1][5] No hepatotoxicity signal appears in published animal studies. No human hepatic safety data are available.

In rodent models: yes. Lee et al. (Cell Metabolism, 2015) demonstrated MOTS-c at 15 mg/kg/day reduces adiposity and improves insulin sensitivity in diet-induced obese mice via AMPK activation in skeletal muscle.^[1] The 2019 metabolomics study confirmed reduced obesity-related plasma metabolite markers.^[5] Human observational data show lower circulating MOTS-c correlates with higher insulin resistance markers in male youth.^[7][8]

Rodent data show fat-mass reduction via AMPK-mediated glucose uptake and fatty acid oxidation.^[1][5] No human weight-loss randomized controlled trial has been published. Weight reduction in humans is not an approved or validated application. Human interventional data for MOTS-c weight management are absent.

Yes, in humans. Circulating MOTS-c in 45–55-year-olds is 11% lower than in 18–30-year-olds; in 70–81-year-olds it is 21% lower.^[6] In parallel, skeletal muscle MOTS-c expression is approximately 1.5-fold higher in older versus younger men, suggesting compensatory tissue upregulation.

MOTS-c levels decline with age in humans (21% lower in 70–81-year-olds vs 18–30-year-olds).^[6] Supplementation improved healthspan markers — grip strength, stride length, walking capacity, metabolic function — in aged mice.^[2] Mechanistic overlap with NAD+ and sirtuin longevity pathways has been identified.^[19] Causal human interventional data are lacking.

Intermittent MOTS-c treatment (5 mg/kg 3×/week subcutaneous) produced a trend toward 6.4% extended median lifespan in aged male mice in Reynolds et al. 2021 — a trend, not a statistically significant result.^[2] The K14Q variant meta-analysis (27,527 subjects) found no longevity association in 736 Japanese centenarians.^[9]

In mice: yes — a twofold improvement in treadmill running distance in middle-aged and old mice treated with MOTS-c at 5 mg/kg 3×/week versus untreated controls.^[2] In humans: serum MOTS-c correlates positively with lower-body muscle force and explosive power (n=20, observational).^[16] No controlled human exercise trial examining exogenous MOTS-c has been published.

No completed Phase 2 or Phase 3 clinical trials for the native MOTS-c sequence have been published as of 2025. Available human data are observational (circulating MOTS-c in aging and obesity cohorts^[6][7][8]) and exercise-induced endogenous response studies.^[3] CB-4211, a MOTS-c analog for obesity, entered early human trials but Phase 2 results have not been published.

Both activate AMPK — metformin via Complex I inhibition (raising AMP/ATP), MOTS-c via folate-AICAR accumulation.^[1][17] The combination is theoretically additive but potentially redundant, and could increase the risk of excessive AMPK activation. No controlled human study has examined the combination.

No controlled study has examined MOTS-c combined with GLP-1 receptor agonists. The two compounds act on different pathways: MOTS-c via the mitochondrial folate-AICAR-AMPK axis; GLP-1 agonists via incretin signaling (GLP-1R, cAMP/PKA). There is no peer-reviewed pharmacokinetic or pharmacodynamic data on the combination.

Published stacking data for MOTS-c are absent from the peer-reviewed literature. SS-31 (elamipretide) is mentioned in self-experiment reports as a mitochondrial-health complement — its mechanism (cardiolipin stabilization) is different from MOTS-c's (AMPK activation via AICAR). No controlled stack study exists for any MOTS-c combination.